Study on the Efficacy and Safety of Mecobalamin in Preventing Taxane-related Peripheral Neuropathy
Recruiting now · Phase 3
Conditions studied: Peripheral Neuropathy Due to Chemotherapy, Peripheral Neuropathy, Chemotherapy-induced
In brief
Some patients receiving taxane-based chemotherapy experience numbness, tingling, or pain in their hands and feet, known as chemotherapy-induced peripheral neuropathy (CIPN). This study aims to find out whether oral mecobalamin can prevent or reduce CIPN. Participants will be assigned to take mecobalamin or to receive no routine mecobalamin prevention during chemotherapy, and outcomes will be compared between groups.
Key facts
- Study ID
- NCT07423390
- Run by
- Qinghai Red Cross Hospital
- People needed
- 326
- Starts
- 2026-02-24
- Expected to finish
- 2029-05-31
- Last updated by the study team
- 2026-04-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically or cytologically confirmed solid tumors, including but not limited to breast cancer, lung cancer, gastric cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and melanoma;
- Age ≥18 years;
- Scheduled to receive adjuvant or neoadjuvant taxane-based chemotherapy (including paclitaxel, nab-paclitaxel, or docetaxel; as monotherapy or in combination) for early-stage disease, or has advanced disease with no prior chemotherapy;
- Life expectancy ≥3 months;
- ECOG performance status 0-2;
- Adequate major organ function (cardiac, hepatic, renal, and bone marrow function);
- Willing and able to provide written informed consent and comply with study procedures.
You may not qualify if…
- Severe impairment of major organ function such that the participant cannot tolerate standard-dose chemotherapy;
- Pre-existing peripheral neuropathy or a history of peripheral neuropathy;
- Skin conditions (e.g., severe palmoplantar keratoderma, active skin infection) that may interfere with assessment of CIPN symptoms;
- Recent use of medications that may alleviate CIPN symptoms;
- Inability to swallow, intestinal obstruction, or other conditions that may affect drug absorption;
- Known hypersensitivity or allergy to mecobalamin;
- Pregnant or breastfeeding women.
Where it is running
- Qinghai Red Cross Hospital — Xining, Qinghai, China (enrolling)
- Beijing Chaoyang Sanhuan Cancer Hospital — Beijing, China (enrolling)
- Affiliated Hospital of Qinghai University — Xining, Qinghai, China
- Affiliated Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital) — Jinan, Shandong, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.